<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880578</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01-30/R3</org_study_id>
    <secondary_id>2019-01-30/R3</secondary_id>
    <nct_id>NCT03880578</nct_id>
  </id_info>
  <brief_title>Quality of Life After Surgery and Radioiodine Treatment</brief_title>
  <acronym>DSR</acronym>
  <official_title>Influence of Surgery and Radioiodine Treatment on Thyroid Function and Quality of Life of Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Lüdenscheid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Lüdenscheid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients are prospectively followed after surgery or radioiodine treatment to
      assess the relationship between thyroid status and their quality of life after thyroid
      ablative treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are frequently dissatisfied with LT4 replacement treatment. The reasons for
      persisting patient complaints are poorly understood. Conversion efficiency and impaired T3/T4
      ratios in athyreotic patients may play a major role. We hypothesised that the extent of
      ablation either by surgery or radioiodine treatment may result in biochemical disequilibria
      between FT3, FT4 and TSH and those may be, in turn, associated with persisting
      symptomatology.

      The study follows patients after surgery or radioiodine therapy as well as a control group
      over half a year, assessing thyroid status, set points, conversion rates, thyroid volume, LT4
      administration and dosing, demographic characteristics and quality of life measures. The
      treatment mode is not part of the study, and determined by criteria and procedures of best
      standard care. For that reason, a randomised or blinded design is not possible.

      Changes and interrelationships between thyroid parameters and QoL measures are analysed
      within-subjects and between treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ThyPRO scale scores (0-100, higher scores indicating worse quality of life)</measure>
    <time_frame>6 months</time_frame>
    <description>quality of life measured by a thyroid specific validated questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of global deiodinase activity (SPINA-GD, see reference calculated parameters)</measure>
    <time_frame>6 months</time_frame>
    <description>efficiency of converting T4 into T3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum concentrations of TSH, FT4, FT3</measure>
    <time_frame>6 months</time_frame>
    <description>biochemical thyroid function tests</description>
  </other_outcome>
  <other_outcome>
    <measure>thyroid volume measured by ultrasound (ml)</measure>
    <time_frame>6 months</time_frame>
    <description>thyroid capacity</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Thyroid; Deficiency</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <description>thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radioiodine</arm_group_label>
    <description>thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>thyroid patients followed without surgery or radioiodine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Sodium</intervention_name>
    <description>thyroid hormone replacement</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>radioiodine</arm_group_label>
    <arm_group_label>surgery</arm_group_label>
    <other_name>LT4</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        thyroid patients in a routine ambulatory setting specialising in Nuclear Medicine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of a thyroid disease requiring surgery or radioiodine treatment

          -  Clinical diagnosis of a thyroid disease requiring follow-up but no ablative treatment
             (controls)

        Exclusion Criteria:

          -  paediatric patients

          -  interfering comorbidity

          -  non-thyroidal illness

          -  pregnancy

          -  psychiatric disease

          -  severe psychological disorder

          -  lack of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Larisch, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rudolf Hoermann, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Lüdenscheid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolf Larisch, Professor</last_name>
    <phone>‭+49 2351 463311‬</phone>
    <email>rolf.larisch@klinikum-luedenscheid.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rudolf Hoermann, Professor</last_name>
    <email>rudolf.hoermann@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear Medicine Klinikum Luedenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <state>NRW</state>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Larisch, Prof</last_name>
      <phone>+492351463311</phone>
      <email>rolf.larisch@klinikum-luedenscheid.de</email>
    </contact>
    <contact_backup>
      <last_name>Hagedorn-Krüger, MD</last_name>
      <phone>+492351463311</phone>
    </contact_backup>
    <investigator>
      <last_name>Rolf Larisch, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hagedorn-Krüger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Larisch R, Midgley JEM, Dietrich JW, Hoermann R. Symptomatic Relief is Related to Serum Free Triiodothyronine Concentrations during Follow-up in Levothyroxine-Treated Patients with Differentiated Thyroid Cancer. Exp Clin Endocrinol Diabetes. 2018 Sep;126(9):546-552. doi: 10.1055/s-0043-125064. Epub 2018 Feb 2.</citation>
    <PMID>29396968</PMID>
  </reference>
  <reference>
    <citation>Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment. Front Endocrinol (Lausanne). 2017 Dec 22;8:364. doi: 10.3389/fendo.2017.00364. eCollection 2017. Review.</citation>
    <PMID>29375474</PMID>
  </reference>
  <reference>
    <citation>Hoermann R, Midgley JEM, Larisch R, Dietrich JW. The role of functional thyroid capacity in pituitary thyroid feedback regulation. Eur J Clin Invest. 2018 Oct;48(10):e13003. doi: 10.1111/eci.13003. Epub 2018 Aug 1.</citation>
    <PMID>30022470</PMID>
  </reference>
  <reference>
    <citation>Hoermann R, Midgley JE, Larisch R, Dietrich JW. Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment. Front Endocrinol (Lausanne). 2015 Nov 20;6:177. doi: 10.3389/fendo.2015.00177. eCollection 2015. Review.</citation>
    <PMID>26635726</PMID>
  </reference>
  <reference>
    <citation>Hoermann R, Midgley JEM, Larisch R, Dietrich JWC. Advances in applied homeostatic modelling of the relationship between thyrotropin and free thyroxine. PLoS One. 2017 Nov 20;12(11):e0187232. doi: 10.1371/journal.pone.0187232. eCollection 2017.</citation>
    <PMID>29155897</PMID>
  </reference>
  <reference>
    <citation>Midgley JE, Larisch R, Dietrich JW, Hoermann R. Variation in the biochemical response to l-thyroxine therapy and relationship with peripheral thyroid hormone conversion efficiency. Endocr Connect. 2015 Dec;4(4):196-205. doi: 10.1530/EC-150056.</citation>
    <PMID>26335522</PMID>
  </reference>
  <reference>
    <citation>Hoermann R, Midgley JE, Larisch R, Dietrich JW. Is pituitary TSH an adequate measure of thyroid hormone-controlled homoeostasis during thyroxine treatment? Eur J Endocrinol. 2013 Jan 17;168(2):271-80. doi: 10.1530/EJE-12-0819. Print 2013 Feb.</citation>
    <PMID>23184912</PMID>
  </reference>
  <reference>
    <citation>Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U, Groenvold M, Rasmussen ÅK, Hegedüs L, Bonnema SJ. Disease-Specific as Well as Generic Quality of Life Is Widely Impacted in Autoimmune Hypothyroidism and Improves during the First Six Months of Levothyroxine Therapy. PLoS One. 2016 Jun 3;11(6):e0156925. doi: 10.1371/journal.pone.0156925. eCollection 2016.</citation>
    <PMID>27257805</PMID>
  </reference>
  <reference>
    <citation>Dietrich JW, Landgrafe-Mende G, Wiora E, Chatzitomaris A, Klein HH, Midgley JE, Hoermann R. Calculated Parameters of Thyroid Homeostasis: Emerging Tools for Differential Diagnosis and Clinical Research. Front Endocrinol (Lausanne). 2016 Jun 9;7:57. doi: 10.3389/fendo.2016.00057. eCollection 2016.</citation>
    <PMID>27375554</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LT4 treatment</keyword>
  <keyword>QoL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data are principally shared depending on compliance with relevant regulations and authorisation</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

